Skip to main content

Febrile Neutropenia

8
Pipeline Programs
13
Companies
10
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
1
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 10 programs with unclassified modality

On Market (1)

Approved therapies currently available

Bayer
CIPROApproved
ciprofloxacin
Bayer
oral1997
396K Part D

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
1
1
ciprofloxacinPhase 3Small Molecule1 trial
Active Trials
NCT00137787Completed51Est. May 2010
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Ceftolozane-TazobactamPhase 4
MSD
MSDIreland - Ballydine
1 program
1
Ceftolozane-TazobactamPhase 41 trial
Active Trials
NCT06342115Recruiting176Est. Dec 2026
Genentech
GenentechCA - Oceanside
1 program
1
Detection of microbial DNA in blood by SeptiFast®Phase 41 trial
Active Trials
NCT00709358Completed2,000Est. Sep 2010
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
Liposomal amphotericin BPhase 42 trials
Active Trials
NCT07530263Not Yet Recruiting18Est. Jun 2027
NCT00421187Terminated20Est. May 2008
Enzychem Lifesciences
1 program
1
EC-18Phase 1/21 trial
Active Trials
NCT03104595Completed28Est. Dec 2019
Kashiv BioSciences
Kashiv BioSciencesNJ - Piscataway
1 program
1
TPI-120 with On body injectorPhase 11 trial
Active Trials
NCT06918587Completed180Est. May 2025
Pfizer
PfizerNEW YORK, NY
1 program
Antibacterial agent for the treatment of febrile neutropeniaN/A1 trial
Active Trials
NCT00945555Completed264Est. Oct 2010
Astellas
AstellasChina - Shenyang
1 program
Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and NeutropeniaN/A1 trial
Active Trials
NCT00723073Completed323Est. May 2008
Coherus Oncology
Coherus OncologyCA - Redwood City
1 program
Pegfilgrastim-CbqvN/A1 trial
Active Trials
NCT04662892Unknown200Est. Dec 2022
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
Liposomal amphotericin BPHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
MSDCeftolozane-Tazobactam
GenentechDetection of microbial DNA in blood by SeptiFast®
Kite PharmaLiposomal amphotericin B
Bayerciprofloxacin
Enzychem LifesciencesEC-18
Kite PharmaLiposomal amphotericin B
Kashiv BioSciencesTPI-120 with On body injector
Coherus OncologyPegfilgrastim-Cbqv
PfizerAntibacterial agent for the treatment of febrile neutropenia
AstellasCaspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia

Clinical Trials (10)

Total enrollment: 3,260 patients across 10 trials

NCT06342115MSDCeftolozane-Tazobactam

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens

Start: Mar 2025Est. completion: Dec 2026176 patients
Phase 4Recruiting
NCT00709358GenentechDetection of microbial DNA in blood by SeptiFast®

Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections

Start: May 2008Est. completion: Sep 20102,000 patients
Phase 4Completed
NCT00421187Kite PharmaLiposomal amphotericin B

Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics

Start: Mar 2007Est. completion: May 200820 patients
Phase 4Terminated
NCT00137787Bayerciprofloxacin

Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases

Start: Apr 2005Est. completion: May 201051 patients
Phase 3Completed
NCT03104595Enzychem LifesciencesEC-18

Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer

Start: Oct 2017Est. completion: Dec 201928 patients
Phase 1/2Completed
NCT07530263Kite PharmaLiposomal amphotericin B

Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)

Start: May 2026Est. completion: Jun 202718 patients
Phase 1Not Yet Recruiting
NCT06918587Kashiv BioSciencesTPI-120 with On body injector

A Comparative Evaluation of Pharmacokinetics and Immunogenicity.

Start: Sep 2024Est. completion: May 2025180 patients
Phase 1Completed
NCT04662892Coherus OncologyPegfilgrastim-Cbqv

An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca

Start: Aug 2020Est. completion: Dec 2022200 patients
N/AUnknown
NCT00945555PfizerAntibacterial agent for the treatment of febrile neutropenia

Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options

Start: Jun 2009Est. completion: Oct 2010264 patients
N/ACompleted
NCT00723073AstellasCaspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia

Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia

Start: Jan 2008Est. completion: May 2008323 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 3,260 patients
13 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.